| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|
aa 861
2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone: structure given in first source. docebenone : A member of the class of benzoquinones that is p-benzoquinone in which the hydrogens are substituted by three methyl groups and a 12-hydroxydodeca-5,10-diyn-1-yl group. | 3.08 | 1 | 0 | 1,4-benzoquinones;
acetylenic compound;
primary alcohol | EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor |
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom. | 2 | 1 | 0 | dibenzoazepine | adrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor |
ly 171883
LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity. | 4.62 | 3 | 0 | acetophenones;
aromatic ether;
phenols;
tetrazoles | anti-asthmatic drug;
leukotriene antagonist |
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively. | 3.39 | 1 | 1 | imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative |
masoprocol
nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata) | 3.08 | 1 | 0 | catechols;
lignan;
tetrol | antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite |
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist | 4.62 | 3 | 0 | chromones | |
pf 5901
alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: structure given in first source; platelet activating factor antagonist | 4 | 2 | 0 | quinolines | |
ici 204,219
zafirlukast: a leukotriene D4 receptor antagonist | 4.62 | 3 | 0 | carbamate ester;
indoles;
N-sulfonylcarboxamide | anti-asthmatic agent;
leukotriene antagonist |
bw-755c
4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine: A dual inhibitor of both cyclooxygenase and lipoxygenase pathways. It exerts an anti-inflammatory effect by inhibiting the formation of prostaglandins and leukotrienes. The drug also enhances pulmonary hypoxic vasoconstriction and has a protective effect after myocardial ischemia. | 3.08 | 1 | 0 | | |
lonapalene
RS 43179: used in treatment of psoriasis | 3.08 | 1 | 0 | naphthalenes;
organochlorine compound | |
ablukast
[no description available] | 4 | 2 | 0 | | |
tepoxalin
tepoxalin : A hydroxamic acid obtained by formal condensation of the carboxy group of 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic acid with the amino group of N-methylhydroxylamine. It is used in veterinary medicine for the control of pain and inflammation caused by musculoskeletal disorders such as hip dysplasia and arthritis in dogs. | 3.08 | 1 | 0 | aromatic ether;
hydroxamic acid;
monochlorobenzenes;
pyrazoles | antipyretic;
apoptosis inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
immunomodulator;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug |
zileuton
[no description available] | 4 | 2 | 0 | 1-benzothiophenes;
ureas | anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug |
wy 48252
Wy 48252: leukotriene D4 antagonist | 4.84 | 4 | 0 | | |
pobilukast
pobilukast: a leukotriene receptor antagonist; an antiasthmatic agent; structure in first source; RN refers to (R-(R*,S*)-isomer | 4 | 2 | 0 | | |
cv 6504
CV 6504: structure given in first source | 3.08 | 1 | 0 | | |
fpl 55712
FPL 55712: inhibitor of SRS-A and LTC4 and LTD4 receptors | 5.02 | 5 | 0 | aromatic ketone | |
sc 41930
SC 41930: leukotriene B4 receptor antagonist; structure in first source | 3.09 | 1 | 0 | | |
ici 198615
ICI 198615: an LTD4 receptor antagonist; SRS-A antagonist; structure given in first source | 3.48 | 2 | 0 | | |
l 648051
L 648051: antagonist of leukotriene D4 receptor; structure in first source | 4 | 2 | 0 | | |
ly 255283
LY 255283: structure given in UD; leukotriene B4 antagonist | 3.09 | 1 | 0 | aromatic ketone | |
bay x 1005
2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source; | 3.09 | 1 | 0 | | |
ly 163443
LY 163443: structure in first source; leukotriene receptor antagonist | 3.07 | 1 | 0 | | |
sc 39070
SC 39070: structure in first source; leukotriene D4 antagonist | 3.07 | 1 | 0 | | |
sr 2640
SR 2640: leukotriene D4 and E4 antagonist | 4.84 | 4 | 0 | quinolines | |
ym 16638
YM 16638: structure in first source; leukotriene D4 receptor antagonist | 3.07 | 1 | 0 | | |
wy 45911
Wy 45911: a leukotriene antagonist with lipoxygenase inhibiting activity; structure given in UD | 3.08 | 1 | 0 | | |
ly 203647
LY 203647: structure in first source; leukotriene D4 and E4 receptor antagonist | 3.07 | 1 | 0 | | |
eth 615
ETH 615: leukotriene B4 and interleukin-8 antagonist; structure in first source | 3.08 | 1 | 0 | | |
ici d2138
ICI D2138: structure given in first source; inhibitor of leukotriene B4 synthesis | 3.09 | 1 | 0 | | |
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes. | 3.08 | 1 | 0 | methoxynaphthalene;
monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic |
2-(phenylmethyl)-1-naphthol
2-(phenylmethyl)-1-naphthol: structure in UD | 3.08 | 1 | 0 | | |
ly 293111
LY 293111: a leukotriene B4 receptor antagonist; structure given in first source | 3.09 | 1 | 0 | aromatic ether | |
7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2h-1-benzopyran-2-propanoic acid
7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid: structure in first source; inhibits leukotriene B4 receptors | 3.09 | 1 | 0 | | |
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin. | 2 | 1 | 0 | (2S)-flavan-4-one;
naringenin | expectorant;
plant metabolite |
via 2291
atreleuton: structure given in first source | 3.09 | 1 | 0 | | |
l 663536
MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase. | 4 | 2 | 0 | aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes | antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist |
scopoletin
[no description available] | 2 | 1 | 0 | hydroxycoumarin | plant growth regulator;
plant metabolite |
leukotriene d4
Leukotriene D4: One of the biologically active principles of SRS-A. It is generated from LEUKOTRIENE C4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene D4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R). | 9.06 | 3 | 1 | dipeptide;
leukotriene;
organic sulfide | bronchoconstrictor agent;
human metabolite;
mouse metabolite |
leukotriene e4
Leukotriene E4: A biologically active principle of SRS-A that is formed from LEUKOTRIENE D4 via a peptidase reaction that removes the glycine residue. The biological actions of LTE4 are similar to LTC4 and LTD4. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene E4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an L-cystein-S-yl group at position 6 (6R). | 1.97 | 1 | 0 | amino dicarboxylic acid;
L-cysteine thioether;
leukotriene;
non-proteinogenic L-alpha-amino acid;
secondary alcohol | |
montelukast
montelukast: a leukotriene D4 receptor antagonist | 3.09 | 1 | 0 | aliphatic sulfide;
monocarboxylic acid;
quinolines | anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist |
l 660,711
[no description available] | 3.48 | 2 | 0 | quinolines | |
sb 201993
(E)-3-((((6-(2-carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid: structure given in first source; a competitive LTB(4) receptor antagonist | 3.09 | 1 | 0 | | |
cinalukast
cinalukast: structure given in first source; orally active LTD4 antagonist; an anti-asthmatic agent. cinalukast : 2,2-Diethylsuccinanilic acid substituted at a meta- position by an (E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl group. It selectively antagonizes leukotriene D4 at the cysteinyl leukotriene receptor, in the human airway, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus. It is used in the treatment of asthma. | 3.07 | 1 | 0 | 1,3-thiazoles;
carboxylic acid | anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist |
bwa 4c
[no description available] | 4 | 2 | 0 | | |
ono 4057
ONO-LB 457: LTB4 receptor antagonist; structure given in first source | 3.09 | 1 | 0 | | |
tmk 688
TMK 688: structure given in first source | 3.08 | 1 | 0 | | |
ticolubant
Ticolubant: a leukotriene B4 antagonist | 3.09 | 1 | 0 | | |
bay x 7195
BAY x 7195: structure given in first source | 3.09 | 1 | 0 | | |
ly 223982
LY 223982: RN & structure in first source; leukotriene B4 antagonist | 3.09 | 1 | 0 | | |
verlukast
verlukast: LTD4 receptor antagonist | 3.09 | 1 | 0 | | |
cp 105696
CP 105696: a leukotriene B4 receptor antagonist; structure in first source | 3.09 | 1 | 0 | | |
mk 0571
[no description available] | 3.09 | 1 | 0 | | |